Related Experiment Video
Updated: Feb 6, 2026

In Silico Clinical Trials for Cardiovascular Disease
Published on: May 27, 2022
Why antioxidant therapies have failed in clinical trials
Adrian M Davies1, Alan G Holt2
171 Falcons Way, Shrewsbury, Shropshire, SY3 8ZG, United Kingdom.
Abstract:
In spite of considerable research, and many clinical trials involving thousands of patients, there is a conspicuous lack of antioxidant therapies available. In this paper we present results for the interaction and neutralization of a free radical species. We adopt two modeling techniques, one based upon Gillespieâ;;s Stochastic Simulation Algorithm and one based upon a discrete Markov chain. An advantage of these models is that they incorporate the number of molecules present per unit volume, and with the Markov chain model, the relative dimensions of these molecules. By means of these models we question the basis of antioxidant therapies based on trapping or scavenging of reactive species. We demonstrate the extraordinary capacity of the enzymatic antioxidant defenses relative to non-enzymatic defenses. We conclude that, if the concentration of an non-enzymatic antioxidant is too low there is little chance of collision and interaction with a free radical species. Furthermore, if the rate of reaction between the free radical and the non-enzymatic antioxidant is below a necessary threshold then the effect of an antioxidant will be dwarfed by the free radical defense systems naturally present. As such we suggest that failure of most antioxidant therapies in clinical trials is to be expected.
Related Concept Videos
Clinical Trials
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview
Statistical Software for Data Analysis and Clinical Trials
Hypothesis: Accept or Fail to Reject?
There are two ways to indicate that the null hypothesis is not rejected. 'Accept' the null...
Trial and Error and Algorithm
Gene Therapy

